[go: up one dir, main page]

MA31365B1 - Utilisation d'inhibiteurs hdac pour le traitement du melanome - Google Patents

Utilisation d'inhibiteurs hdac pour le traitement du melanome

Info

Publication number
MA31365B1
MA31365B1 MA32330A MA32330A MA31365B1 MA 31365 B1 MA31365 B1 MA 31365B1 MA 32330 A MA32330 A MA 32330A MA 32330 A MA32330 A MA 32330A MA 31365 B1 MA31365 B1 MA 31365B1
Authority
MA
Morocco
Prior art keywords
melanoma
treatment
pharmaceutically acceptable
acceptable salt
hdac inhibitor
Prior art date
Application number
MA32330A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39641895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31365(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31365B1 publication Critical patent/MA31365B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un inhibiteur hdac, plus spécifiquement, ou d'un sel pharmaceutiquement acceptable de celui-ci pour la fabrication de compositions pharmaceutiques pour le traitement du mélanome ; l'utilisation d'un inhibiteur hdac ou d'un sel pharmaceutiquement acceptable de celui-ci dans le traitement du mélanome ; un procédé de traitement d'animaux à sang chaud, mammifères inclus, particulièrement d'humains, souffrant du mélanome, par administration à l'animal nécessitant un tel traitement d'une dose efficace contre la maladie d'un inhibiteur hdac ou d'un sel pharmaceutiquement acceptable de celui-ci.
MA32330A 2007-05-11 2009-11-09 Utilisation d'inhibiteurs hdac pour le traitement du melanome MA31365B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91734507P 2007-05-11 2007-05-11
US93827207P 2007-05-16 2007-05-16
PCT/US2008/063136 WO2008141114A1 (fr) 2007-05-11 2008-05-09 Utilisation d'inhibiteurs hdac pour le traitement du mélanome

Publications (1)

Publication Number Publication Date
MA31365B1 true MA31365B1 (fr) 2010-05-03

Family

ID=39641895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32330A MA31365B1 (fr) 2007-05-11 2009-11-09 Utilisation d'inhibiteurs hdac pour le traitement du melanome

Country Status (15)

Country Link
US (2) US20110034531A1 (fr)
EP (1) EP2155193A1 (fr)
JP (1) JP2010526830A (fr)
KR (1) KR20100016376A (fr)
CN (1) CN101677995A (fr)
AU (1) AU2008251499A1 (fr)
CA (1) CA2684114A1 (fr)
CL (1) CL2008001363A1 (fr)
IL (1) IL201439A0 (fr)
MA (1) MA31365B1 (fr)
MX (1) MX2009012179A (fr)
RU (1) RU2009145803A (fr)
TN (1) TN2009000449A1 (fr)
TW (1) TW200911231A (fr)
WO (1) WO2008141114A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
US20110034531A1 (en) 2011-02-10
KR20100016376A (ko) 2010-02-12
JP2010526830A (ja) 2010-08-05
RU2009145803A (ru) 2011-06-20
IL201439A0 (en) 2010-05-31
TN2009000449A1 (en) 2011-03-31
MX2009012179A (es) 2009-12-01
US20110288144A1 (en) 2011-11-24
AU2008251499A1 (en) 2008-11-20
CA2684114A1 (fr) 2008-11-20
CL2008001363A1 (es) 2008-12-19
EP2155193A1 (fr) 2010-02-24
CN101677995A (zh) 2010-03-24
WO2008141114A1 (fr) 2008-11-20
TW200911231A (en) 2009-03-16

Similar Documents

Publication Publication Date Title
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MX2023007192A (es) Inhibidores de prmt5.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
UA85702C2 (ru) 3-[ 4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды как ингибиторы продуцирования цитокинов, предназначены для лечения хронических воспалительных заболеваний
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EP2178869A4 (fr) Composés d'indole en tant qu'inhibiteurs de nécrose cellulaire
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
EA201101507A1 (ru) Способы лечения солидных опухолей
WO2009144555A8 (fr) Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA31706B1 (fr) Formulations galéniques de composés organiques
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA201001094A1 (ru) Производные индазола
MA37886B1 (fr) Nouvelles pyridinones bicycliques
NO20091185L (no) Piperidinderivater
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
ATE554084T1 (de) N-hydroxyacrylamidverbindungen